Department of Molecular Epidemiology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
Department of Molecular Epidemiology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands; Max Planck Institute for Biology of Ageing; Joseph-Stelzmann-Str. 9b, D-50931 Köln (Cologne), Germany.
Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt A):2742-2751. doi: 10.1016/j.bbadis.2017.09.017. Epub 2017 Sep 22.
Human ageing is an extremely personal process leading across the life course of individuals to large population heterogeneity in the decline of functional capacity, health and lifespan. The extremes of this process are witnessed by the healthy vital 100-year-olds on one end and the 60-year-olds suffering from multiple morbid conditions on the other end of the spectrum. Molecular studies into the basis of this heterogeneity have focused on a range of endpoints and methodological approaches. The phenotype definitions most prominently investigated in these studies are either lifespan-related or biomarker based indices of the biological ageing rate of individuals and their tissues. Unlike for many complex, age-related diseases, consensus on the ultimate set of multi-biomarker ageing or lifespan-related phenotypes for genetic and genomic studies has not been reached yet. Comparable to animal models, hallmarks of age-related disease risk, healthy ageing and longevity include immune and metabolic pathways. Potentially novel genomic regions and pathways have been identified among many (epi)genomic studies into chronological age and studies into human lifespan regulation, with APOE and FOXO3A representing yet the most robust loci. Functional analysis of a handful of genes in cell-based and animal models is ongoing. The way forward in human ageing and longevity studies seems through improvements in the interpretation of the biology of the genome, in application of computational and systems biology, integration with animal models and by harmonization of repeated phenotypic and omics measures in longitudinal and intervention studies. This article is part of a Special Issue entitled: Model Systems of Aging - edited by "Houtkooper Riekelt".
人类衰老过程是一个极其个体化的过程,在个体的整个生命历程中,功能能力、健康和寿命的下降存在着很大的人群异质性。这一过程的极端情况在健康的百岁老人和患有多种疾病的 60 岁老人身上都可以看到。对这种异质性基础的分子研究集中在一系列终点和方法学方法上。这些研究中最突出的表型定义是个体及其组织的生物学衰老率的与寿命相关的或基于生物标志物的指数,而不是许多复杂的与年龄相关的疾病。与许多复杂的与年龄相关的疾病不同,对于遗传和基因组研究的最终多生物标志物衰老或与寿命相关的表型集尚未达成共识。与动物模型类似,与年龄相关的疾病风险、健康衰老和长寿的标志包括免疫和代谢途径。在许多关于年龄的( epi )基因组学研究和人类寿命调节研究中,已经确定了许多潜在的新的基因组区域和途径,APOE 和 FOXO3A 代表了最稳健的基因座。细胞和动物模型中少数基因的功能分析正在进行中。在人类衰老和长寿研究中,未来的发展方向似乎是通过改善对基因组生物学的解释、应用计算和系统生物学、与动物模型的整合以及通过协调纵向和干预研究中的重复表型和组学测量来实现。本文是题为“衰老模型系统”的特刊的一部分-由“ Houtkooper Riekelt”编辑。